Leading the Fight Against MASH
Our innovative research led to the first breakthrough in MASH treatment. And we’re just getting started.
Pam, patient advocate
Delivering a Breakthrough Treatment
Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. Left untreated, MASH can lead to progressive liver scarring, cirrhosis, liver failure, liver cancer, need for transplant and premature mortality. Our goal is to halt or reverse liver scarring (fibrosis) and resolve MASH before patients experience the devastating complications of cirrhosis.
Madrigal’s ambitious research program led to the first and only U.S. Food and Drug Administration (FDA)-approved treatment in MASH.
Shining a Light on MASH
Shining a Light on MASH
Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is a serious form of fatty liver disease that occurs when fat in the liver becomes toxic, damaging liver cells. The chronic and progressive nature of the disease can cause significant damage over time, including inflammation and scarring, or fibrosis. Fibrosis can progress quickly and be unpredictable, often resulting in cirrhosis and decompensated liver disease.
MASH is the leading cause of liver transplantation in the U.S. for women and is expected to soon become the leading cause for men.
Careers & Culture
Interested in transforming care of people living with MASH? Learn more about Madrigal’s purpose, Core Values and culture.
References
Alkhouri N, McCullough AJ. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol (N Y). 2012;8(10):661-8.
Heyens LJM, Busschots D, Koek GH, et al. Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment. Front Med (Lausanne). 2021;8:615978.
Noureddin M, Vipani A, Bresee C, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113(11):1649-1659.
Wong RJ, Singal AK. Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019. JAMA Netw Open. 2020;3(2):e1920294.